Williams MC, et al. - This substudy of the SCOT-HEART randomized controlled trial evaluated the clinical impact of noncardiac findings and potential changes to surveillance scans with the application of new lung nodule guidelines. Those causing symptoms or requiring further investigation, follow-up or treatment were clinically significant noncardiac findings. The results of this study revealed that clinically significant noncardiac findings were identified in 10% of patients undergoing coronary computed tomography angiography (CCTA). They suggested that application of new lung nodule guidelines will decrease the cost of surveillance, without the risk of missing malignancy.